ERBB2 and breast cancer: For the analyses of molecular subtypes (Table 3), postmenopausal women tended to have breast cancer of HER2‐overexpressing (multivariate‐adjusted OR = 2.99, 95% CI: 1.49‐5.97) and triple‐negative (multivariate‐adjusted OR = 2.16, 95% CI: 1.02‐4.56) subtypes.